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78Objective: Surgical mitral valve repair carries an elevated perioperative risk in the presence of severely reduced
ventricular function and relevant comorbidities. We sought to assess the feasibility of catheter-based mitral valve
repair using a clip-based percutaneous edge-to-edge repair system in selected patients at high surgical risk with
mitral regurgitation grade 3 or worse.
Methods: Between 2002 and January 2011, 202 consecutive patients without prior mitral valve surgery (age 75
9 years; 63% were male) with symptomatic functional (65%), degenerative (27%), or mixed (8%) mitral regur-
gitationwere treatedwith a percutaneous clip system for approximation of the anterior andposteriormitral leaflets.
Risk for mitral valve surgery was considered high in terms of a mean logistic European System for Cardiac Op-
erative Risk Evaluation of 44% (range, 21%–54%). Preprocedural left ventricular ejection fraction was 35% or
less in 36%of patients.An interdisciplinary heart teamof cardiologists and cardiac surgeons discussed all patients.
Results: Percutaneous clip implantation was successful in 186 patients (92%). Patients were treated with 1 clip
(n ¼ 125; 62%), 2 clips (n ¼ 64; 32%), or 3 or more clips (n ¼ 7; 3%). Reduction in mitral regurgitation from
pre- to postprocedure was significant (P<.0001) and remained stable within the first 12 months in the majority
of patients. Thirty-day mortality was 3.5% (7/202 patients). Hospital stay was 12 10 days, and median inten-
sive care unit stay was 1 day (range, 0–45 days). Eleven patients required surgical valve repair/replacement at
a median of 38 days (0–468 days) after percutaneous clip implantation.
Conclusions: Clip-based percutaneous mitral valve repair is a safe, low-risk, and effective therapeutic option in
symptomatic patients with a high risk for surgery and does not exclude later surgical repair. (J Thorac Cardiovasc
Surg 2012;143:78-84)Surgical mitral valve repair (MVR) is the gold standard
treatment for severe mitral regurgitation (MR) in degenera-
tive disease and has superseded mitral valve replacement as
the treatment of choice in the majority of patients in the
United States and Western Europe. In experienced centers,
surgical MVR can be performed with approximately 0%
mortality and extremely low complication rates.1 Success-
ful surgical MVR in patients with preserved ventricular
function restores quality of life and life expectancy and ise Departments of Cardiovascular Surgerya and General and Interventional
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The Journal of Thoracic and Cardiovascular Surgetherefore recommended as treatment even in asymptomatic
patients if the likelihood of repair is high.2 In addition, the
invasiveness of surgical MVR is favorably reduced if min-
imally invasive techniques through a right-sided lateral
minithoracotomy are implemented as the standard of care.3
In functional mitral valve disease, however, the results of
surgical MVR are worse and procedural risks are higher.4 If
MR is caused by ventricular dysfunction (eg, dilated car-
diomyopathy), repair of the valve may restore valve func-
tion but does not treat the underlying ventricular disease.
Comorbidities such as renal dysfunction, previous cardiac
surgery, and a history of stroke or myocardial infarction
are common, thereby also increasing the risk of surgical
treatment. With an aging population and improved medical
therapy, the number of patients with functional MR and rel-
evant comorbidities will further increase. The Euro Heart
Survey revealed that patients with reduced ventricular func-
tion or significant comorbidities and patients aged more
than 80 years were unlikely to be referred for mitral valve
surgery at all.5 It is for this growing population of high-risk
patients that less-invasive treatment alternatives have been
explored.ry c January 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
EVEREST II ¼ Endovascular Valve Edge-to-
Edge Repair Study
MR ¼ mitral regurgitation
MVR ¼ mitral valve repair
NYHA ¼ New York Heart Association
TR ¼ tricuspid regurgitation
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DPercutaneous MVR techniques currently have been de-
veloped for annuloplasty (direct or through a coronary sinus
approach), left ventricular chamber remodeling, chordae re-
placement, or leaflet repair.
The MitraClip device (Abbott Vascular, Menlo Park, Ca-
lif) uses a steerable catheter to deliver 1 or more clips to the
anterior and posterior leaflet via transseptal access. The pro-
cedure imitates the surgical technique previously described
by Alfieri and colleagues,6 which connects the anterior and
posterior mitral leaflets with a suture and thus creates
a ‘‘double orifice’’ mitral valve, thereby reestablishing leaf-
let coaptation and reducing MR. The procedure has been
described in detail.7,8
Because of the excellent surgical results of surgical
MVR, MitraClip therapy is only performed in patients car-
rying a high surgical risk at the University Heart Center. A
heart team consisting of interventional cardiologists, expe-
rienced mitral valve surgeons, and echocardiographers re-
views every case and decides on the appropriate therapy.
Figure 1 demonstrates a flow-chart on how treatment deci-
sions are made by the heart team at the University Heart
Center. The majority (80%) of patients treated with theSevere Mitral Val
Contraindication
high oper
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FIGURE 1. Flow-chart on Heart Team decisions in patients with severe MR a
coronary artery bypass grafting; LV, left ventricular; MVR, mitral valve repair.
The Journal of Thoracic and CMitraClip device would have fulfilled the exclusion criteria
for the recently published Endovascular Valve Edge-to-
Edge Repair Study (EVEREST II) trial,9 a randomized
comparison of surgical and interventional MVR using the
MitraClip device, mainly because of severely reduced ven-
tricular function in functional MR. Nevertheless, the num-
ber of patients presenting with severe MR and high
surgical risk has markedly increased since the introduction
of percutaneous techniques at the University Heart Center.
This makes a change in referral policy obvious because
we now see patients who had not been referred to the Uni-
versity Heart Center for MVR before.
We report on our results of percutaneous MVR using the
MitraClip system in a consecutive series of 202 patients
who were deemed high risk for surgical MVR. All proce-
dures were performed in a hybrid operation theater by a ded-
icated team of cardiologists and cardiac surgeons. The
primary objective of this analysis was to assess the efficacy
of the MitraClip system in reduction of MR grade and func-
tional patient improvement as expressed by NewYork Heart
Association (NYHA) functional class.
MATERIALS AND METHODS
Patients
From 2002 to 2010, a total of 1764 patients underwent isolated mitral
valve operations and interventions at the University Heart Center, of
whom 202 consecutive patients with a mean age of 75  9 years (range,
47–93 years) were treated with the MitraClip system for approximation
of the anterior and posterior mitral leaflet (September 2008 to January
2011). Severity of MR was graded in accordance with the American Soci-
ety of Echocardiography guidelines.10 The majority of patients (98.5%)
presented with grade 3þor 4þ symptomatic MR of functional (65%), de-
generative (27%), or mixed (8%) origin and underwent joint evaluation
by an interdisciplinary panel consisting of cardiovascular surgeons and car-
diologists. High surgical risk was based on logistic European System for
Cardiac Operative Risk Evaluation (euroSCORE) calculation11 or the pres-
ence of severely reduced ventricular function or relevant comorbidities.
The overall mean logistic euroSCORE was 36% (range, 21%–54%).ve Regurgitation 
s for surgery or
ative risk 
 decision 
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omitant cardiac surgery 
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t the University Heart Center Hamburg. AVR, Aortic valve repair; CABG,
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TABLE 1. Baseline patient characteristics
N 202
Age, y 75  9
Men, n (%) 127 (63)
Prior surgical MVR, n (%) 1 (0.5)
Logistic euroSCORE,% (range) 36 (21–54)
Hypertension, n (%) 148 (74)
Hypercholesterolemia, n (%) 127 (63)
Diabetes, n (%) 71 (35)
Chronic obstructive pulmonary disease, n (%) 69 (34)
Renal failure, n (%) 104 (52)
Chronic heart failure, n (%) 169 (84)
Atrial fibrillation, n (%) 129 (64)
Coronary artery disease, n (%) 145 (72)
Prior CABG, n (%) 70 (35)
Cardiomyopathy, n (%)
Ischemic 82 (41)
Dilated 54 (27)
Valvular 9 (5)
MR cause, n (%)
Functional 131 (65)
Degenerative 55 (27)
Mixed 16 (8)
MR severity, n (%)
2þ (mild to moderate) 3 (1.5)
3þ (moderate to severe) 107 (53)
4þ (severe) 92 (46)
NYHA functional class, n (%)
II 4/195 (2)
III 121/195 (62)
IV 70/195 (36)
LV ejection fraction,% 44  16
LV, Left ventricular.
FIGURE 2. MR at baseline, postprocedure, and 12 months after interven-
tional MVR using the MitraClip device (Abbott Vascular, Menlo Park, Ca-
lif) (P<.0001, chi-square test). MR, Mitral regurgitation.
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ischemic, 27% dilated, 5% valvular). Mean ejection fraction was
44%  16% (range, 12%–77%). Coronary artery disease was present in
72% of patients, and 35% had a history of coronary artery bypass grafting
(CABG). Other cardiovascular risk factors included hypertension (74%),
renal failure (52%), diabetes (35%), and chronic obstructive pulmonary
disease (35%). Baseline patient characteristics are shown in Table 1.
Percutaneous Mitral Valve Repair Procedure
All MitraClip device interventions were performed as previously de-
scribed.6,7 In brief, with the patient under general anesthesia and using
fluoroscopic and transesophageal 2- and 3-dimensional echocardiographic
guidance, the MitraClip device was advanced via the transseptal route
across the mitral annulus into the left ventricle. With the 2 arms of the
clip extended, the device was retracted to capture the anterior and posterior
leaflet at the height of the regurgitant jet, and subsequently closed to ap-
proximate the mitral leaflets, thereby emulating the surgical edge-to-
edge technique introduced by Alfieri and colleagues.6 If the reduction in
MR was inadequate with 1 device, the device was removed or a second de-
vice placed. Procedural success was defined as the implantation of at least 1
clip and residual MR of grade 2þor less.
Follow-up
Clinical and echocardiographic follow-up evaluation was scheduled at
the time of hospital discharge and 12 months after the procedure. If a return
visit was hindered by comorbidities, reevaluation was restricted to80 The Journal of Thoracic and Cardiovascular Surgetelephone follow-up. At clinical visits, transthoracic echocardiography
was carried out and NYHA functional class was assessed. Post-
interventional severity of MR was graded as previously described12,13
according to the technique of Foster and colleagues14 following the Amer-
ican College of Cardiology guidelines.
Statistics
Data are presented as mean  standard deviation or median plus (inter-
quartile) range for continuous variables, and as counts and percentages for
categoric variables. Continuous variables were compared by Student t test.
The Kaplan–Meier method was used for time-to-event analysis.RESULTS
Median procedure duration, device time (from transsep-
tal puncture to withdrawal of the clip delivery system
from the left atrium), and fluoroscopy time were 180 min-
utes (range, 60–560 minutes), 66 minutes (range, 15–395
minutes), and 28 minutes (range, 7–152 minutes), respec-
tively. Percutaneous MVR was successful in 186 of 202 pa-
tients (92%) as defined by MR of 2þ or less (Figure 2).
Thirty-day mortality was 3.5% (7/202 patients). The reduc-
tion in MR from pre- to postprocedure was significant
(P<.0001) and remained stable within the first 12 months
in the majority of patients. In successfully treated patients,
60 had a reduction by 1 MR grade (30%), 104 had a reduc-
tion by 2 MR grades (52%), and 26 had a reduction by 3
MR grades (13%). In 12 patients (6%), no reduction in
MR could be achieved (Figure 3). A single clip was im-
planted in 125 patients (62%), 2 clips were implanted in
64 patients (32%), and 3 or more clips were implanted in
7 patients (4%). In 16 patients (8%), clip implantation
was not achieved (n ¼ 6) or did not reduce MR to less
than grade 3þ (n ¼ 10).ry c January 2012
FIGURE 3. Acute reduction in MR from baseline to postprocedure after
interventional MVR using the MitraClip device. Mean: 1.7  0.8,
n ¼ 202. MR, Mitral regurgitation.
FIGURE 5. Cumulative survival after interventional MVR using the Mi-
traClip device (Kaplan–Meier analysis).
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DEchocardiographic data did not reveal a difference in left
ventricular end-diastolic and end-systolic diameters from
baseline to 12 months.
Data on preprocedural tricuspid regurgitation (TR) were
available in 193 patients. Of those, only 20.2% presented
with a concomitant TR grade of 3 or greater. In the group
of patients with 12 months echocardiographic data on TR
(n ¼ 66), the majority (53.1%) did not show any change
in degree of TR or even decreased TR (17.1%), whereas
29.7% showed an increase of TR by 1 (25.0%), 2
(3.1%), or 3 (1.6%) grades.FIGURE 4. Change in NYHA functional class from baseline to discharge
and during 12 months follow-up after interventional MVR using the
MitraClip device (P ¼ .0001, chi-square test). NYHA, New York Heart
Association.
The Journal of Thoracic and CPatients were less symptomatic after MitraClip device
implantation as expressed by a significant reduction in
NYHA functional class (P< .0001) after the procedure
and during follow-up (Figure 4). Mean acute reduction in
NYHA classification was0.9 0.7. At hospital discharge,
74% of patients showed an improvement in NYHA class of
at least 1 class. The proportion of patients in NYHA class I
or II at discharge and after 12 months was 59% and 65%,
respectively (Figure 4). Overall survival at 12 months was
89.6% (Figure 5).
Patients were hospitalized for a median of 9 days (range,
1–73 days). Kaplan–Meier estimation revealed a 1-year sur-
vival of 89.6% (Figure 5).
Eleven patients required surgical reintervention because
of failed repair (n¼ 3) or recurrent severeMR (n¼ 7), or de-
spite good valve function (n ¼ 1) at a median of 38 days
(range, 0–468 days) after MitraClip device implantation.
Six patients underwent operation at the University Heart
Center.15 Five patients underwent MVR, and 6 patients had
mitral valve replacement using biological prostheses. Injury
of the mitral leaflets caused by prior MitraClip device treat-
ment was present in 6 patients, influencing the surgical strat-
egy towardmore complex repair techniques in 3 patients and
mitral valve replacement in 1 patient. Figure 6 shows typical
clip-related lesions after intraoperative clip detachment with
leaflet defects and chordal ruptures. Both valves were re-
paired successfully despite structural defects. All patients
undergoing operation after failedMitraClip device implanta-
tion at the University Heart Center are alive with adequate
valve function at the latest follow-up of 9.8  7.3 months
(range: 1–19 months). Five patients underwent operation at
outside hospitals after MitraClip device implantation, and 2
of them died of unknown reasons in hospital after mitral
valve replacement. One patient underwent combined
CABG and MVR despite good valve function (MR 1þ) at
an outside hospital 58 days after clip implantation.ardiovascular Surgery c Volume 143, Number 1 81
FIGURE 6. Clip-related lesions at the anterior and posterior mitral valve leaflets with chordal rupture (arrows). Both valves were repaired successfully.
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In patients with severe MR deemed at high risk for sur-
gery, percutaneous MitraClip therapy proved to be a safe
and acceptably effective alternative to surgical MVR. Acute
reduction in MR by 1 grade or more in 92% of patients led
to an improvement in NYHA functional class in the major-
ity of patients (60% NYHA class I or II at discharge, 72%
at 1-year follow-up). On the other hand, only 38% of pa-
tients at discharge and 28% at 12-month follow-up
achieved a post-interventional MR grade of 1þ or less,
which would be accepted as a result after surgical repair.
Degree of TR was not or positively affected by MitraClip
therapy in 70.3% of patients, whereas an increase of TR de-
veloped in 29.7% of patients within 12 months follow-up.
The study is limited by the fact that 12-month echocardio-
graphic follow-up was available in only 88 patients; there-
fore, unbiased interpretation of long-term data is not
possible at this time. Nevertheless, patients benefited from
a safe and less-invasive procedure. Although 30-daymortal-
ity was only 3.5%, 1-year mortality was 10.4%, reflecting
the reduced state and the complex morbidity of the patients.
In comparison with the recently published EVEREST II
trial,9 our patients reflect a different patient cohort. In the
MitraClip arm of EVEREST II, 73% of patients had degen-
erative disease and 49% were in NYHA class I or II,
whereas 73% of our patients had functional or mixed MR
and 98% were in NYHA class III or IV. Eighty percent of
our patients would have fulfilled the exclusion criteria for
the EVEREST II trial.
In EVEREST II, MitraClip-treated patients benefited
from lower complication rates at 30 days, yet by 1 year,
20% of those patients required surgical MVR because of re-
current or persistent severe MR. In addition, 46% of pa-
tients showed post-interventional MR 2þ or more. The
only modest reduction in MR severity might be associated
with favorable short- and midterm outcomes, but surgical
series suggest that residual MR predicts adverse long-
term clinical outcomes. It is for this reason that we do not
offer percutaneous MVR to low-risk patients at the Univer-
sity Heart Center. Moreover, the intention-to-treat analysis82 The Journal of Thoracic and Cardiovascular Surgeof the EVEREST II trial showed that patients with func-
tional MR, aged more than 70 years, or with a left ventric-
ular ejection fraction less than 60% might particularly
benefit from percutaneous MVR. This particular subgroup
of patients should be evaluated for percutaneous MVR after
thorough evaluation by a dedicated heart team, although it is
obvious that, like surgery, the clip cannot treat the underly-
ing ventricular disease.
Eleven of our 202 patients (5%) required surgical MVR
or replacement after percutaneous repair because of failed
procedure or insufficient MR reduction. One patient under-
went combined CABG and surgical MVR despite good
valve function after MitraClip device implantation. Patients
undergoing operation at the University Heart Center sur-
vived the procedure and showed good clinical outcome de-
spite elevated surgical risk. Nevertheless, 2 patients
undergoing operation at an outside hospital died during
the hospital stay, underlining the fact that post-
interventional mitral valve surgery is even more complex
and should be performed by experienced mitral valve sur-
geons only. Surgery was complicated but not impeded by
previous clip implantation, although MVR was only possi-
ble in 5 patients and the other 6 patients underwent mitral
valve replacement with biological prostheses. Even in
high-risk patients, surgical treatment remained an option
and proved to work as a successful ‘‘bail-out’’ therapy for
failed MitraClip repair. High surgical risk does not neces-
sarily translate into inoperability.
In contrast with concerns of many cardiac surgeons, the
implementation of a percutaneous mitral valve program
did not have a negative influence on our center’s surgical
mitral valve volume. To the contrary, the surgical volume
even increased because of a positive impact of patients
who were referred for interventional treatment but turned
out to be good surgical candidates and therefore conse-
quently underwent surgical MVR (Figure 7).
CONCLUSIONS
Given an aging population and a steady increase in car-
diovascular diseases including functional mitral valvery c January 2012
FIGURE 7. Volume of surgical and percutaneousmitral valve treatment at
the University Heart Center Hamburg 2002–2010.
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Dregurgitation, the need for less-invasive mitral valve thera-
pies is evident. Interventional cardiologists and cardiac
surgeons as a heart team have the knowledge and under-
standing of mitral valve pathology and repair techniques.
It seems only natural that any technique of interventional
MVR should be performed in close collaboration and after
detailed discussion among the heart team. As members of
the team, cardiac surgeons should now consequently take
the chance to adopt these new techniques and make them
part of their portfolio.References
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Dr A. Marc Gillinov (Cleveland, Ohio). That was an excellent
and timely article. You present results in 202 patients receiving the
MitraClip device. Your 30-day mortality was only 1%. The mean
decrease inMR gradewith the procedurewas 1.7, and, remarkably,
at 1 year, 72% of surviving patients are in functional class I or II.
So I will ask you 3 fairly straightforward questions, that is, who,
how, and when.
First is the who question, and that is the most important. You
have described the patients who are treated, who they are, and
how you get to them. It looked to me from the article, which
you were kind enough to provide, that it tends to be people with
functional MR who have often undergone previous cardiac sur-
gery. My main question with ‘‘who,’’ though, is this: As your ex-
perience has increased and you have developed a greater comfort
zone, are you seeing the indications creep into the surgical popu-
lation? Are you seeing more patients in whom you would say,
we could operate on him, but let’s try percutaneous first?
Dr Treede. Actually, that is not the case. We do not switch our
indications. We still perform surgery in all patients who are oper-
able, and we have no reason to change this unless the results of sur-
gery are still better than the results of the MitraClip therapy in
terms of reduction ofMR, and becausewe know the data published
by Sarano and colleagues that patients with remaining MR 2+
don’t do as well in the long-term follow-up compared with patients
without MR. So this should be the reason not to switch indications.
Especially in patients with organic MR, myxomatous disease, or
even Barlow valves, the MitraClip device will probably come to
its limits.
Dr Gillinov. The second question is how, not how do you do the
procedure, but how should we judge success of the procedure?
There seem to be 2 ways in which people judge the percutaneous
repair. One is, how did we do with the MR, and the other is, how
are the patients doing in terms of with functional class? For the
MR, you declare procedural success if the MR is 2+ or less, but
I note that at 1 year, only 28% of patients have MR that is 1+ or
less (a surgical success). That doesn’t sound very good. But, on
the other hand, with approximately three quarters in NYHA class
I or II, you could say the procedure is successful for the patient.
How should we judge success?
Dr Treede. I would still suggest that we judge success by the
grade of MR, because NYHA class is a subjective thing, and it
is dependent on other variables (eg, medical therapy) that are not
this measurable. So if we clearly stick to the echo data, we will
find out what proportion the MitraClip therapy has on that better
functional result. So I would still do that, although it is not thisardiovascular Surgery c Volume 143, Number 1 83
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ifice may complicate echo measurements.
Dr Gillinov. The final question is when. When should we oper-
ate if the clip has not worked? Clearly you get scar tissue and in-
growth, and the surgical repair will be more challenging months
down the road. Given what you know now, would you recommend
to us to operate early if the patient leaves the catheter laboratory
with 3+ MR?
Dr Treede. Yes, we have seen that it is harder to get the clip out
once it is really ingrown into the valve. On the other hand, I would
still make the decision dependent on the degree of MR, and I
would not prophylactically operate on a patient who does not
have severe regurgitation after the clip treatment. But once you
have a severe regurgitation and the clip did fail, then it is definitely
easier to do the operation earlier.
Dr Gillinov. Thank you. That was excellent.
Dr Gorav Ailawadi (Charlottesville, Va). I commend you on
doing this important study. Can you give us more insight on those
11 patients who required a mitral operation as to the number of
clips that were inserted and if that affected the ability to repair
the valve? What was the risk in those 11 patients? You mention
an 18% mortality. Do you have an idea of what their euroSCORE
or Society of Thoracic Surgeons’ risk was before determining
placement of a MitraClip device?
Dr Treede. These were all in patients with a high euroSCORE,
but as you know, a high euroSCORE does not mean that they are,
by definition, inoperable, so we were able do the operations. Un-
fortunately, we do not have too much information on those patients
who died after surgery, because they died in outside hospitals.
We cannot say with regard to the small numbers right now if the
number of clips has any influence on the surgical outcome. One
can, of course, assume that more clips would probably do more
harm to the mitral valve, but having operated on some of themmy-
self, I can say that the injury that the clip leaves at the leaflets is, in84 The Journal of Thoracic and Cardiovascular Surgemost cases, not so harmful that the valve is no longer repairable. So
I cannot answer this part of the question right now.
Dr Robert Dion (Genk, Belgium). I am impressed by your pio-
neering work, but I have a few questions. First, you evaluate the
results by considering the amount of residual MR or the NYHA
class. But what about the remodeling of the left ventricle (the di-
mensions and volumes), how did it evolve with the time? Indeed,
in principal, I have an objection to call a success a residual grade 2
MR in functional MR. Maurice Sarano has shown that even mod-
erate MR has a deleterious influence on survival when LV function
is altered. Therefore, I think you should select the patients who are
absolutely inoperable, because you leavemost of themwith a grade
2 MR, which is again not innocuous in a bad ventricle.
My second point is that you say the mortality is approximately
1%. But we have heard that it can increase to 18% when a patient
has to undergo reoperation after a failed clip.
Dr Treede. We are absolutely of your opinion, and we would
still only include patients in the MitraClip program who are at
high risk for surgery but probably not completely inoperable, be-
cause inoperability has another aspect. Once you have done the
MitraClip placement and see an increase in MR, then you should
probably have a way to treat the patients afterward. If the patients
are completely inoperable, it is hard to include them in the program
because we would no longer have an exit strategy for a patient in
whom the clip has failed or even does harm to the valve.
The 2 patients dying after surgery because of failed implanta-
tion died in an outside hospital. It is hard for us to judge if that
was due to surgeons who did not have much experience with mi-
tral valve operations. I would definitely suggest and strongly rec-
ommend that only very experienced mitral valve surgeons
perform reoperations in patients after the clip. So this is at least
something we would recommend. I don’t think that 18% is the
true mortality for patients undergoing surgery after clip
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